Stock Code: 002433 stock abbreviation: Guangdong Taiantang Pharmaceutical Co.Ltd(002433) Announcement No.: 2022-005 Guangdong Taiantang Pharmaceutical Co.Ltd(002433)
2021 annual performance forecast
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions. 1、 Performance forecast for 2021 1 1. Performance forecast period: January 1, 2021 to December 31, 2021
2. Expected performance: √ loss \uf0a3 turning loss into profit \uf0a3 rising in the same direction \uf0a3 falling in the same direction
The current report of the project is the same period of last year
Losses attributable to listed companies: 788 million yuan – 798 million yuan
Profit: 22.2257 million yuan
The net profit of shareholders decreased over the same period of last year: 3645.45% – 3690.44%
Deducting non recurring losses: 332 million yuan – 342 million yuan
Loss: 32.2847 million yuan
The net profit after profit decreased by 928.35% – 959.33% over the same period of the previous year
Basic earnings per share loss: 1.03 yuan / share – 1.04 yuan / share earnings: 0.03 yuan / share
2、 The relevant financial data of this performance forecast have not been audited by an accounting firm. 3、 Explanation of performance change reasons
The main reasons for the decline of the company’s performance in 2021 compared with the same period of last year are as follows:
1. During the reporting period, the company repaid 900 million corporate bonds, resulting in insufficient marketing working capital investment, a sharp decline in operating income, and an operating loss of about 332 million yuan to 342 million yuan.
2. During the reporting period, the operating performance of factor company Guangdong kangaido Digital Health Technology Co., Ltd. and its subsidiary Guangdong Hongxing Group Co., Ltd. fell sharply, resulting in the impairment of goodwill of 314 million yuan and 131 million yuan respectively
Yuan, with a total goodwill impairment of 445 million yuan.
4、 Other relevant instructions
This performance forecast is the preliminary calculation result of the company’s financial department. The specific financial data will be disclosed in detail in the company’s 2021 annual report. Please make careful decisions and pay attention to investment risks.
Guangdong Taiantang Pharmaceutical Co.Ltd(002433) board of directors January 29, 2002
